Metagenomi Therapeutics, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.38 USD
−78.06 M USD
52.30 M USD
26.31 M
About Metagenomi Therapeutics, Inc.
Sector
Industry
CEO
Jian Irish
Website
Headquarters
Emeryville
Founded
2016
IPO date
Feb 9, 2024
Identifiers
3
ISIN US59102M1045
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene editing toolbox, therapeutic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MGX is 1.46 USD — it has decreased by −4.61% in the past 24 hours. Watch Metagenomi Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Metagenomi Therapeutics, Inc. stocks are traded under the ticker MGX.
MGX stock hasn't changed in a week, the month change is a −17.14% fall, over the last year Metagenomi Therapeutics, Inc. has showed a −39.17% decrease.
We've gathered analysts' opinions on Metagenomi Therapeutics, Inc. future price: according to them, MGX price has a max estimate of 12.00 USD and a min estimate of 7.00 USD. Watch MGX chart and read a more detailed Metagenomi Therapeutics, Inc. stock forecast: see what analysts think of Metagenomi Therapeutics, Inc. and suggest that you do with its stocks.
MGX stock is 4.14% volatile and has beta coefficient of 1.41. Track Metagenomi Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Metagenomi Therapeutics, Inc. there?
Today Metagenomi Therapeutics, Inc. has the market capitalization of 54.44 M, it has increased by 2.68% over the last week.
Yes, you can track Metagenomi Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Metagenomi Therapeutics, Inc. is going to release the next earnings report on Apr 1, 2026. Keep track of upcoming events with our Earnings Calendar.
MGX earnings for the last quarter are −0.55 USD per share, whereas the estimation was −0.58 USD resulting in a 5.90% surprise. The estimated earnings for the next quarter are −0.61 USD per share. See more details about Metagenomi Therapeutics, Inc. earnings.
Metagenomi Therapeutics, Inc. revenue for the last quarter amounts to 8.66 M USD, despite the estimated figure of 7.82 M USD. In the next quarter, revenue is expected to reach 7.33 M USD.
MGX net income for the last quarter is −20.39 M USD, while the quarter before that showed −19.91 M USD of net income which accounts for −2.44% change. Track more Metagenomi Therapeutics, Inc. financial stats to get the full picture.
No, MGX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 14, 2026, the company has 202 employees. See our rating of the largest employees — is Metagenomi Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Metagenomi Therapeutics, Inc. EBITDA is −86.79 M USD, and current EBITDA margin is −159.66%. See more stats in Metagenomi Therapeutics, Inc. financial statements.
Like other stocks, MGX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Metagenomi Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Metagenomi Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Metagenomi Therapeutics, Inc. stock shows the strong sell signal. See more of Metagenomi Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.